1. Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma
- Author
-
Rajneesh K. Joshi, Mohd Anas Sheikh, Neerja Kushwaha, Amit Kumar Biswas, Sanjeevan Sharma, Joseph Philip, and Sudeep Kumar
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Chemotherapy ,Neutrophil Engraftment ,Platelet Engraftment ,business.industry ,medicine.medical_treatment ,030106 microbiology ,CD34 ,General Medicine ,medicine.disease ,Gastroenterology ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Cell dose ,Internal medicine ,medicine ,Original Article ,030212 general & internal medicine ,Stem cell ,business ,Multiple myeloma - Abstract
BACKGROUND: Treatment with high-dose chemotherapy and stem cell transplantation has prolonged survival in patients of multiple myeloma (MM). A dose-response relationship between number of CD34+ cells infused and leukocyte and platelet recovery, exists. Patients receiving dose of 5 × 10(6)/kg (category 3), the mean (SD) neutrophil engraftment time was 11.3 (0.5) days, 10.6 (0.9) days, and 10.2 (1.3) days respectively. Platelet engraftment time was 12.4 (2.60) days, 10.6 (1.14) days, and 11.2 (1.64) days for category 1, 2, and 3 patients, respectively. Correlation co-efficient between CD 34+cell dose and days for neutrophil and platelet engraftment was found to be −0.24 and −0.20, respectively. Time for neutrophil engraftment was found to be significantly associated with CD34+ cell dose category. CONCLUSION: CD 34+ cell dose appears as the strongest predictor of leukocyte and platelet engraftment. CD 34+ cell dose of >5.0 × 10(6) cells/kg leads to an accelerated neutrophil and platelet engraftment in patients of MM.
- Published
- 2022
- Full Text
- View/download PDF